, a bio/informatics shared resource is still "open for business" - Visit the CDS website


  1. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) PLoS One 11(6): e0157368
    › Primary publication · 27310713 (PubMed) · PMC4911051 (PubMed Central)
  2. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA (2016) Cell Rep 14(10): 2289-300
    › Primary publication · 26947080 (PubMed) · PMC4794398 (PubMed Central)
  3. Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. Zhang P, Samuels DC, Lehmann B, Stricker T, Pietenpol J, Shyr Y, Guo Y (2016) Brief Bioinform 17(2): 224-32
    › Primary publication · 26249222 (PubMed) · PMC5974936 (PubMed Central)
  4. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS (2016) BMC Cancer : 143
    › Primary publication · 26908167 (PubMed) · PMC4763445 (PubMed Central)
  5. Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS (2016) BMC Cancer : 275
    › Primary publication · 27090641 (PubMed) · PMC4835864 (PubMed Central)
  6. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA (2016) Cancer Res 76(16): 4850-60
    › Primary publication · 27231203 (PubMed) · PMC4987189 (PubMed Central)
  7. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA (2016) Mol Cancer Ther 15(11): 2598-2608
    › Primary publication · 27528706 (PubMed) · PMC5807013 (PubMed Central)
  8. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, Pietenpol JA, Ferguson AD (2016) J Med Chem 59(24): 11079-11097
    › Primary publication · 28002961 (PubMed)
  9. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Lehmann BD, Pietenpol JA, Tan AR (2015) Am Soc Clin Oncol Educ Book : e31-9
    › Primary publication · 25993190 (PubMed)
  10. Subtyping of triple-negative breast cancer: implications for therapy. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Cancer 121(1): 8-16
    › Primary publication · 25043972 (PubMed) · PMC4270831 (PubMed Central)